Marshall Wace, LLP Infla Rx N.V. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.18 - $1.74 $56,634 - $83,511	-47,995 Reduced 58.66%	33,824 $58,000
Q1 2024 May 15, 2024	BUY	$1.47 - $2.03 $67,352 - $93,010	45,818 Added 127.27%	81,819 $126,000
Q4 2023 Feb 14, 2024	BUY	$1.25 - $2.75 $29,375 - $64,625	23,500 Added 187.98%	36,001 $58,000
Q3 2023 Nov 14, 2023	BUY	$2.66 - $4.33 $33,252 - $54,129	12,501 New	12,501 $37,000
Q2 2022 Aug 15, 2022	SELL	$0.78 - $1.9 $26,795 - $65,270	-34,353 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.83 - $4.48 $62,865 - $153,901	34,353 New	34,353 $63,000

12.9M

19.3K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $99M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.